Summary Most randomised clinical trials of cancer treatment include a few hundred patients or less. Recent statistical papers advocate that sometimes thousands of patients should be entered. In this paper I show that for certain types of cancer trials the 'thousands policy' is not required while for others it is desirable but not feasible. In the latter case other strategies should be considered, such as two-stage phase III studies or parallel studies leading to overviews. There is, however, an important subset of trials for which application of the thousands policy is both necessary and feasible. The key to progress lies partly in the achievement of greater recruitment rates in trials of common cancers and partly in greater inter-group collaboration.
The past 20 years have seen a rapid increase in the number of clinical trials designed to evaluate treatments for cancer. The role of medical statisticians in the design of these trials has been central, particularly in phase III studies, where the concept of randomised allocation of treatments is now recognised as a fundamental principle. Although the debate between proponents of randomisation and those who favour methodology using historical controls or clinical data bases lingers, there is now emerging an important and perhaps more pressing controversy -that of the number of patients required in a randomised clinical trial.
In all but a few exceptions (e.g. Byar, 1973; Cancer Research Campaign Working Party, 1980; Nolvadex Adjuvant Trial Organization, 1985; Riley et al., 1986) randomised clinical trials in cancer have, until now, included several hundreds of patients or less. On the other hand, a strong school of opinion has emerged which advocates that sometimes thousands of patients, rather than hundreds, should be entered into randomised trials (Yusuf et al., 1984) . The notion of such a quantum leap in the desired size arouses much emotion among investigators, both because it casts aspersions on the value of previous and current trials and because of the perceived difficulty of achieving such large sizes in the future. As a consequence the debate has generated much heat.
In this paper I attempt to clarify the statistical arguments behind the 'thousands of patients' policy and then highlight the areas of cancer research to which these arguments apply and to which they do not. I will show that for certain types of cancer research, the 'thousands' policy is not required, and for other types it is desirable but not feasible. This will raise the question of what to do in such circumstances. Finally I will point out the type of cancer research where the 'thousands' policy is both desirable and feasible. be interested in the time to local recurrence, metastatic spread and death, as well as acute and chronic toxicity from the treatment. For the purpose of planning the sample size of the study it is usually possible to identify a single major end-point, which is used to summarise treatment outcome. This is often chosen to be time to death or time to first recurrence of disease; in the following discussion we assume that such an end-point is appropriate.
The number of patients required in the study is calculated with respect to the selected major end-point. Specifically, the number of patients is chosen so as to guarantee a high probability (usually 90%) of detecting a statistically significant difference (usually at 5% level) on the condition that a certain difference, 6, actually exists. If the true difference is greater than 6 then the chance of showing a significant difference will be greater than 90%. Conversely, if the true difference is smaller than 6 then the trial will have a less than 90% chance of showing significance; indeed the chances of showing significance are reduced quite dramatically if the true difference is considerably less than 6. The assumption is that the end-point is a surival rate, which is 50% for the control group; however, the numbers here remain essentially unchanged for survival rates between 15 and 85%.
Br. J. Cancer (I 989) 59, [396] [397] [398] [399] [400] therapy in rectal cancer to detect increases in the 5-year survival rate from the current 35% to 55%. Adjuvant treatments available, such as radiotherapy, cannot be expected to increase the absolute survival rate by more than 5-10% (i.e. to 40-45%). As shown in Table I , trials based on detecting a 20% increase are likely to fail to detect a difference half this size. Nevertheless, a 10% increase in 5-year survival, or even a 5% increase, would be clinically worthwhile, especially in a common disease such as rectal cancer.
Planning for moderate and more realistic treatment differences has a marked effect on the number of patients to be entered in the study. Statistics has its own version of the inverse-square law: to detect a difference a fractionf smaller, you need 1/f2 as many patients. For example, to detect half the difference you need four times the number of patients. Figure 1 shows the number of patients required for reliable detection of a given treatment difference 6. In this figure, it is assumed that the control treatment has a survival rate of 50%, rather typical of the 5-year rate for diseases such as colonic cancer or rectal cancer. The figure shows that for detection of improvements of 10%, the number of patients required is about 1,000, and this number rises very rapidly as the target difference becomes smaller. This is the basis of the statistical argument for entering a thousand or more patients. It should be noted that the required numbers are of the same order as those shown in Figure 1 as long as the control group's survival rate is between 20 and 80%. Outside this range the required numbers become smaller. This point will be elaborated later.
Requirements for very large trials
In an article entitled 'Why do we need some large and simple randomized trials', Yusuf et al. (1984) clearly set out the philosophy and requirements for such studies. Five necessary conditions are described:
1. The question posed by the trial must be clinically important. 2. The disease must be common. 3. The treatments must be widely applicable (i.e. able to be used in most hospitals).
Difference in survival rates (%) Figure 1 Number of patients (deaths) required to give a 90% chance of showing a significant (5%) improvement (control survival rate = 5%).
4. The end-point should be simple to measure and the entry protocol should be simple. 5. Only a modest treatment difference should be expected. We have already discussed Item 5.
Items 1-3 are interrelated. A question might be considered clinically important without necessarily addressing a common disease or widely applicable treatments. However, both these aspects will naturally enhance the question's importance and its relevance to the wider clinical profession. Moreover, there is a need for the question to be seen as important, so that clinicians are encouraged to participate. In addition, if the treatments are widely available, then there will be opportunity for a greater range of clinical participation. Similarly, the more common the disease the greater the number of potential entrants to the study.
Item 4 refers to the simplicity of the study procedures. To encourage participation the study should be designed to fit as unobtrusively as possible into normal clinical practice. Collection of data should usually be restricted to the minimum required to answer the main questions posed. These authors are implicitly critical of current cancer trials, most of which enter a few hundreds of patients. The next section examines which types of randomised cancer clinical trials do not require the very large numbers that have been advocated.
Trials for which we do not always need very large numbers (1,000 or more) It was argued above that large numbers are required when: (a) the treatment outcome is summarised by the time to an adverse event and (b) the expected treatment difference, 6, is at best moderate.
Most cancer trials are based on the analysis of time to an adverse event. The most common alternative end-point is the response or non-response of manifest disease to a therapy. The argument regarding the numbers of patients is not substantially altered by the use of tumour response as an end-point. There is, however, a class of trials where a more precise measure of treatment effect may be used. Superficial bladder cancer may be removed by localised procedures such as surgery, intravesical chemotherapy or a combination. Patients with this disease tend to have recurrences of their tumours which are again superficial and which may be repeatedly eradicated by local treatment. The response to the initial procedure may thus be measured by the subsequent rate of recurrences in the patient, a more sensitive measure of treatment effect than the occurrence or non-occurrence of a single event. Using such an end-point one would expect to be able to detect treatment differences with hundreds rather than thousands of patients. This has indeed been verified by recently published results (Denis et al., 1987; Tolley et al., 1988) .
It was argued before that in clinical trials it is usual that the expected improvement from a new treatment is realistically only moderate. There are exceptions. For example, several uncontrolled studies of adjuvant chemotherapy for osteosarcoma (Jaffe et al., 1974; Cortes et al., 1974; Eilber et al., 1978; Rosen et al., 1981) had suggested a large improvement in relapse-free rate. When a randomised study to test this hypothesis was conducted (Link et al., 1986) it was reasonable to plan to enter a few hundred patients. In fact, the discovery of a large treatment difference led to early termination of this study.
One further aspect needs to be considered, namely the rate at which the adverse event will occur. The statistical argument above is somewhat simplified. The determining factor for the ability of a trial to detect a given treatment difference is not actually the number of patients, but the number of events. For example, suppose the end-point is time to death; a trial with 1,000 patients of whom 500 will die will be able to detect a given treatment difference with equal reliability as a trial with 2,000 patients but the same number of deaths, 500. Figure 1 shows that about 500 deaths will reliably detect a difference of 10% in survival rates. If P is the proportion of deaths observed among patients in the trial, then the number of patients required will be 500/P. Figure 1 illustrates the case where P is approximately 0.5, when about 1,000 patents will be needed. However, for diseases where P is close to I a trial size of around 500 will be sufficient to detect a moderate treatment difference.
A high mortality rate also has consequences for the desired expected treatment difference, 6. Suppose a disease has a median survival time of only 6 months. If the death rate is constant throughout the first 2 years after treatment then by 2 years there will be approximately 5% of survivors. One needs to ask not only what is the expected improvement, 6, from a new treatment, but also what is the smallest clinically worthwhile improvement. This latter quantity will depend on the relative toxicity of the new treatment, the relative inconvenience to the patient or other factors. It is quite likely that increasing the median survival by less than 3 months would be seen as insufficient to justify routine use of the new treatment. Trials should not usually be conducted unless the expected improvement from the new treatment is at least equal to the smallest clinically worthwhile improvement. In diseases with high mortality this will often be at least 50% increase in the median survival time. This translates into an increase in survival rate from about 5% to 14% at 2 years. As mentioned above, this improvement can be detected without very large numbers, since the control group's survival rate is less than 20%. In fact the 9% improvement is a large relative increase and requires only a few hundred patients to detect. It is a moot point whether treatments which can realistically be expected to produce such benefits are always chosen for study, and one could argue that there are far too many studies of therapies which give little chance of such a major improvement; but by conducting a trial with a few hundred patients we, at least, do not risk missing a clinically important difference because of too small a trial. There are several common cancers that have a high mortality rate (Table II) . The above arguments support the use of moderate-size trials in these diseases.
Trials which need to be large but cannot be Although the considerations of the previous section exempt a substantial proportion of cancer clinical trials from needing large numbers of patients, there remains probably more than half of the current randomised phase III studies which are not exempted. Nevertheless, if we consider the requirements for a successful large trial, we find many barriers to the 'large trial' approach.
Rare diseases
There is no accepted definition of a 'rare' disease. For the purposes of this discussion I use a cut-off point of less than 2,000 new cases per annum in England and Wales. A list of some such cancers where clinical trials are currently of interest is given by Table III . To enter 1,000 or more patients into a national trial would require entry of most of the newly diagnosed patients. While high proportions of entry can be achieved where patients are usually referred to specialist centers (e.g. acute myeloid leukaemia and osteosarcoma) it must be recognised that, where a wide distribution of general surgeons or physicians treats the patients, the proportion of entry to the trials is currently below 10% and mostly in the range 0-4% (Tate et al., 1978) . It is unlikely that this proportion could be raised quickly to 50% or more, so very large trials in these rare diseases are probably not feasible, at least at the national level. Attempts to overcome the problems in rare disease have been made by running international collaborative trials (e.g. European Osteosarcoma Intergroup, 1986; Medical Research Council, 1987) . These efforts are quite difficult to organise and it is too early to assess their achievements. (1987) .
Treatments which eventually could, if shown to be worthwhile, become widely available, are genuine candidates for randomised comparisons but there may need to be an alternative strategy to the very large study. Two possible strategies are outlined below.
Two-stage phase III studies
One way to address the problems described above is to divide phase III studies into two stages (Ellenberg & Eisenberger, 1985) . In the first stage a moderate number of patients (a few hundred) are entered and the results evaluated. Should the results reveal a trend towards benefit (without necessarily reaching statistical significance) further investment in extending the applicability of the treatment might be made and a very much larger study (the second stage) then conducted. This resembles what sometimes happens in practice, except that the moderate-size stage is initially planned as the definitive study. Consequently, there is an unwillingness to continue investigation of the treatment, and also too strong an emphasis on the statistical significance of the result. A possible weakness in this twostage strategy is the added length of time it may take to complete the full phase III programme, due to the need to assess the results of the first stage before deciding whether to proceed to the very large trial.
Parallel studies (leading to overviews) A second strategy is to accept that one's own individual study will, by itself, probably not provide a definitive evaluation of the therapy, but to design the trial in conjunction with other groups of investigators who are studying the identical (or nearly identical) question. The idea is that the study should form one of a series of parallel studies, and that the results from these studies should be combined at some future date to achieve the necessary precision to detect any moderate but clinically worthwhile improvement. One's own study, to contribute substantially to the overview, should constitute an appreciable fraction (> 10%) of the few thousand patients who may eventually be required. The methodology for combining the results of parallel studies (known as 'overview') has been well described (Peto, 1987; Antiplatelet Triallists' Collaboration, 1988; Early Breast Cancer Triallists' Collaborative Group, 1988 
Conclusion
In the conclusion to their paper, Yusuf et al. (1984) Finally, there are many important questions in cancer treatment which do indeed lend themselves to the very large trial approach. Some of these are listed in this paper; no doubt others can be identified or will emerge. Parallel studies will also be useful for these questions. The key to progress lies partly in the achievement of greater recruitment rates in trials of common cancers and partly in greater inter-group collaboration.
Although I take responsibility for the ideas expressed in this paper, much was distilled from a meeting entitled, ' (Haybittle, 1988 
